ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Academic Oncologists Reluctant To Give ESAs In Adjuvant Breast Cancer Setting.

December 7, 2007

New Jersey Insurers To Cover Patient Care Costs In Trials.

January 14, 2000

In Brief: USC Norris Opens Topping Tower March 21; Postal Service To Sell Breast Cancer Stamps

March 15, 1996

Spending Bill Expected At White House Any Day Now; NIH Awaits 15% Increase.

October 27, 2000

Advisors Approve New Grant Programs In Breast Pre-Malignancy, Lung Inflammation

November 17, 2006

DCCR Advisory Committee Delays Planned Expansion Of Promising Community Clinical Oncology Program

July 21, 1978